Other · developed by 35Pharma Inc., a GSK company
HS235 is a drug studied in pulmonary hypertension and heart failure with preserved ejection fraction.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07123779 | Phase 1/2 | Pulmonary Hypertension | Recruiting | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Heart Failure With Preserved Ejection FractionPulmonary Hypertension
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →